FLSM
PASG icon

Frazier Life Sciences Management’s Passage Bio PASG Stock Holding History

Frazier Life Sciences Management’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-87,911
Closed -$1.16M – 52
2023
Q3 		$1.16M Sell
87,911
-4,589
-5% -$75.4K 0.08% 51
2023
Q2 		$1.74M Sell
92,500
-95,346
-51% -$1.89M 0.1% 47
2023
Q1 		$3.6M Hold
187,846
– – 0.26% 45
2022
Q4 		$5.18M Hold
187,846
– – 0.32% 38
2022
Q3 		$4.7M Sell
187,846
-62,615
-25% -$2.47M 0.36% 36
2022
Q2 		$11.8M Hold
250,461
– – 1.12% 24
2022
Q1 		$15.5M Buy
+250,461
New +$20.6M 1.32% 25

Other funds holding PASG

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Frazier Life Sciences Management's PASG Position: Q4 2023 in Review

Frazier Life Sciences Management sold out of Passage Bio (PASG) in Q4 2023, closing a stake of 87,911 shares — an estimated $1.16M sold.

Frazier Life Sciences Management first reported a position in PASG in Q1 2022 and held it in 7 quarters. The position peaked at $15.5M in Q1 2022. 50 funds tracked by Wall St. Rank hold PASG as of Q4 2023.

  • Frazier Life Sciences Management reported no remaining Passage Bio position as of Q4 2023 after selling out during the quarter.
  • Frazier Life Sciences Management sold 87,911 Passage Bio shares in Q4 2023, an estimated $1.16M.
  • Frazier Life Sciences Management first reported a position in Passage Bio in Q1 2022 and held it in 7 quarters.
  • Frazier Life Sciences Management's Passage Bio position peaked at $15.5M in Q1 2022.
  • 50 funds tracked by Wall St. Rank held Passage Bio as of Q4 2023.

Based on Frazier Life Sciences Management's 13F filing for Q4 2023, filed 14 Feb 2024.